Breast Cancer Care for patients with metastatic disease

Breast Cancer Care for patients with metastatic disease - BRE-4-MED

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00013726

Enrollment

Registered

2018-02-06

Start date

2018-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C50 C76 C77 C78 C79 C80

Interventions

Group 1: Cooperating physicians will collect data from the treatment of patients with metastatic. These include age, sex and information about the therapy chosen. This information is collected by all

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Advanced or metastatic breast cancer (ICD10: C50; C76-C80) 18 years and older written consent of the patient or legal representative to the baseline and follow-up interviews

Exclusion criteria

Exclusion criteria: <18 years No advanced or metastatic breast cancer

Design outcomes

Primary

Measure	Time frame
guideline adherence Proportion of guideline compliance (S3 guideline breast cancer) Treatments on all treatments during the observation period (18 months); Questionnaire to attending physician and reports to the cancer registry	—

Secondary

Measure	Time frame
Overall surviva; Timeframe up to 18 months after diagnosis. Information is requested from the cancer registry and the registration officel, Progression-free survival; Timeframe up to 18 months after diagnosis. Report by attending physician, report by patient, verification by information from cancer registry, breast cancer-specific mortality; Timeframe up to 18 months after diagnosis. Information is requested from the cancer registry and the registration office, quality of life; Collected using the validated EORTC-2 (Global Health) questionnaire (paper-based: baseline, 3, 6, 12 and 18 months after enrollment, and on a regular (14 day) per patient app), timeframe: QoL over 18 months after diagnosis, toxicity; Registration of side effects and treatment discontinuations related to treatment by questionnaire and cancer registry information; Period up to 18 months after diagnosis, freedom from symptoms; Timeframe up to 18 months after diagnosis Report of progression by attending physician, report by patient	—

Measure

Time frame

Overall surviva; Timeframe up to 18 months after diagnosis. Information is requested from the cancer registry and the registration officel, Progression-free survival; Timeframe up to 18 months after diagnosis. Report by attending physician, report by patient, verification by information from cancer registry, breast cancer-specific mortality; Timeframe up to 18 months after diagnosis. Information is requested from the cancer registry and the registration office, quality of life; Collected using the validated EORTC-2 (Global Health) questionnaire (paper-based: baseline, 3, 6, 12 and 18 months after enrollment, and on a regular (14 day) per patient app), timeframe: QoL over 18 months after diagnosis, toxicity; Registration of side effects and treatment discontinuations related to treatment by questionnaire and cancer registry information; Period up to 18 months after diagnosis, freedom from symptoms; Timeframe up to 18 months after diagnosis Report of progression by attending physician, report by patient

—

Countries

Germany

Contacts

Public ContactKirsten Haas

Institut für Klinische Epidemiologie und Biometrie (IKE-B) der Universität Würzburg

Kirsten.Haas@uni-wuerzburg.de+49 (0)931 / 201 47311

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026